B of A Securities Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
B of A Securities analyst Tazeen Ahmad initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $35.
B of A Securities analyst Tazeen Ahmad initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $35.